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Introduction: Human bronchioloalveolar carcinoma (BAC) is a
disease with an evolving definition. “Pure” BAC, characterized by a
bronchioloalveolar growth pattern and no evidence of stromal,
vascular, or pleural invasion, represents only 2 to 6% of non-small
cell lung cancer (NSCLC) cases, but up to 20% of NSCLC cases
may contain elements of BAC. This imprecise definition makes it
difficult to perform epidemiologic analyses or to generate accurate
animal models. However, because BAC appears to behave clinically
differently from adenocarcinoma, a better understanding of this
disease entity is imperative.
Methods/Results: At the BAC Consensus Conference in 2004, our
committee discussed issues relevant to BAC epidemiology, patho-
genesis, and preclinical models.
Conclusions: Elucidation of molecular events involved in BAC
tumorigenesis will allow for more precise epidemiologic studies and
improved animal models, which will enable development of more
effective treatments against the disease.
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The definition of the disease entity known as human bron-chioloalveolar carcinoma (BAC) is evolving. Classically,
BAC is considered a subtype of pulmonary adenocarcinoma,
involving a peripheral tumor with distinct clinicopathologic
features and representing 2 to 6% of non-small cell lung
cancer (NSCLC) cases.1 The histopathology of “pure” BAC
is characterized by a bronchioloalveolar lepidic growth pat-
tern and no evidence of stromal, vascular, or pleural invasion.
More recently, others have proposed a less stringent classi-
fication of BAC, which describes any adenocarcinoma with
features of BAC as a subset of BAC.2 In this particular study,
this latter definition, which may account for some 20% of
NSCLC cases, includes pure BAC, BAC with focal invasion,
and adenocarcinoma with BAC features. Interestingly, in this
analysis, clinical pattern and pathologic stage, but not the
degree of invasion on histologic examination, predicted pa-
tient survival.
To add to the inconsistency and imperfect adherence to
the pathological definition of BAC, the term bronchioloal-
veolar is also frequently used in experimental pathology. It
has been applied to a wide range of hyperplasias and tumors
in peripheral lung, prompting confusion among investigators
interested in developing models for human lung carcinogen-
esis. Mouse lung tumors (carcinomas) that histologically
mimic classic human BACs are actually extremely rare or
nonexistent. Despite this, mouse models of lung cancer are
still useful as a major component of multidisciplinary ap-
proaches toward understanding basic aspects of the disease,
such as lung tumorigenesis, pathogenesis, and treatment.
At the Consensus Conference on BAC, our committee
discussed current knowledge about the epidemiology of BAC
and reviewed state-of-the-art animal models of lung cancer in
general and BAC in particular, with a special focus on ovine
pulmonary adenocarcinoma (OPA), mouse lung-tumor mod-
els induced by chemicals or generated transgenically, and
orthotopic models. Feline and canine BAC models have been
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reviewed elsewhere.3,4 Recommendations were made on how
to improve the current status of knowledge about BAC
epidemiology, pathogenesis, and preclinical models.
EPIDEMIOLOGY
The incidence of BAC appears to have increased four-
fold from 1955 to 1990,5 but the absence of a standardized
definition of BAC limits epidemiologic investigation because
of difficulties in accurate case ascertainment. Classically,
BAC has unique morphological features and clinical behav-
ior, with growth along alveolar septae without stromal inva-
sion, an indolent course, and higher prevalence in young,
nonsmoking women. The clinical course may be more slowly
growing than other types of lung cancers, but after treatment,
these tumors often recur in multiple areas of the lung. Patients
with mixed-type adenocarcinoma with BAC features on his-
tology seem to have a better response to epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors,6–8 and
never-smoking patients with mixed-type adenocarcinoma
with BAC features have the best response,9 making such
patients an ideal population in which to test EGFR-inhibitor
therapy.
BAC is less strongly associated with smoking than
other NSCLC, and occurs more commonly among younger
women. The presence of other lung diseases (e.g., diffuse
fibrosis) is associated with increased BAC risk. One study
reported an occupational association with motor-freight oc-
cupations.10
Future Tasks
The roles of viral infection, lifestyle, ethnic and gender
differences, environmental exposures, and genetic polymor-
phisms need to be evaluated. A major emphasis of molecular
epidemiologic studies of BAC should include assessment of
EGFR mutations (see Pathogenesis section) in sample sizes
large enough to evaluate potential effect modifiers and con-
founders, including ethnicity and smoking habits. Candidate
germline polymorphisms and gene-by-environment interac-
tions may be examined as risk factors and as possible prog-
nosis factors.
Considering BAC frequency, the most efficient study
designs to carry out the research detailed above remain
case-control and case-only studies; cohort studies are not
likely to produce the number of BAC cases needed to exam-
ine multiple variables. All molecular epidemiologic investi-
gations need to use standardized questionnaires and collect
blood and tissue samples (with proper collection, storage, and
preparation techniques).
PATHOGENESIS
Cancers arise from a multistep pathway involving the
accumulation of genetic lesions in oncogenes and tumor-sup-
pressor genes.11 The precise steps involved in the pathogenesis
of lung adenocarcinoma have not yet been determined.
Only a limited number of studies have analyzed the
contribution of different oncogenes and tumor-suppressor
genes to BAC pathogenesis.12–15 Overall, TP53 and RAS
genes are less often mutated in BAC than in adenocarcinoma,
and the most frequently affected chromosomal regions of loss
of heterozygosity in BAC are 8q and 17q.16,17 However,
several studies have shown that various subtypes of BAC—
mucinous, nonmucinous, and sclerosing—might have distinct
molecular oncogenic signatures. For example, the incidence
of codon 12 KRAS mutations is strikingly high, from 70 to
100%, in the mucinous subtype of BAC. By contrast, there is
a lower incidence of KRAS mutations in the other two
subtypes of BAC and in invasive lung adenocarcinomas.
TP53 mutations are more frequently found in the nonmuci-
nous and sclerosing types of BAC than mucinous tumors. The
incidence of EGFR mutations, which have been associated
with sensitivity to new targeted agents such as gefitinib
(Iressa) and erlotinib (Tarceva),18–20 seems to be higher in
BAC than in non-BAC adenocarcinomas.21 This could ex-
plain why patients with BAC are more apt to respond to the
EGFR inhibitors, but a thorough gene-copy and DNA-se-
quencing analysis of BAC samples has not yet been per-
formed.
Future Tasks
Current priorities include 1) improving the understand-
ing of various stages of invasive lung adenocarcinoma in
general and BAC in particular, using techniques such as
mutational profiling, expression profiling, gain–loss analyses,
proteomics, etc., 2) identifying a molecular signature for
BAC; 3) elucidating etiologies for BAC; 4) developing bio-
markers to distinguish BAC from other NSCLC tumor types;
and 5) determining a multistep pathway for BAC.
PRECLINICAL MODELS
OPA
Human BAC is strikingly morphologically similar to a
contagious form of pulmonary cancer in sheep known as
jaagsiekte (OPA),22–24 which occurs in endemically affected
flocks worldwide23,25 and is caused by a betaretrovirus, jaag-
siekte sheep retrovirus (JSRV).23,24,26,27 OPA arises from
secretory epithelial cells that retain their secretory function
after transformation.23,28 An obvious question, still unre-
solved, is whether viral agents cause BAC in humans.
The biology of JSRV has been intensively studied for
the last 15 years. The virus is a simple retrovirus with gag,
pol, and viral envelope protein (env) genes and an open
reading frame of unknown function, orf X.24,29 JSRV host-
cell interactions and molecular mechanisms of oncogenesis
are being investigated.24,30 The viral receptor for JSRV in
human cells, which are permissive for the virus, is hyaluron-
idase 2.31 Receptor-independent and -dependent oncogenic
mechanisms of transformation have been identified in various
cell lines, but, remarkably, env is sufficient to transform
mouse, rat, and human cell lines.31–34 Evidence implicates
involvement of the PI-3K/AKT and other signal-transduction
pathways,30,34–36 but the exact means by which env proteins
induce their activation and cell transformation have not been
elucidated. Analysis of viral integration sites in tumor DNA
suggests that there may be at least two common integration
sites for JSRV in OPA, which supports the hypothesis that
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insertional mutagenesis also may be involved in OPA onco-
genesis.37,38
Attempts have been made to identify JSRV-related
proteins or genomic sequences in human BAC.39–41 Further
studies are required to determine whether pathogenic JSRV-
like viruses are present in the human population.
Future Tasks
OPA represents an excellent outbred animal model of
BAC, which provides researchers with unique opportunities
to investigate a number of issues. Specifically, the highest
priorities using this model should be 1) studying the sequence
of events in the pathogenesis of tumors; 2) determining the
oncogenes, tumor-suppressor genes, and signaling pathways
involved in OPA tumorigenesis; and 3) establishing whether
there is a viral etiology to human BAC. Although potentially
more cumbersome than experiments involving mice, thera-
peutic intervention trials should be considered in OPA.
MOUSE LUNG TUMOR MODELS
Histopathology and Classification
In mouse lung, most tumors occur in the peripheral
compartment and arise from alveolar type II cells in the
pulmonary acinus. They are characterized by lamellar bodies
and are positive for surfactant-associated proteins (SP-A and
SP-C). Lesions are adenomas or, more rarely, carcinomas,
with solid, papillary, tubular, or combined growth patterns. In
mouse lungs, the lepidic or scale-like pattern, which is the
hallmark of human BAC, is usually limited to hyperplasias,
mostly of type II cells, which at times may be difficult to
distinguish from neoplasia. Hyperplastic lesions resembling
human atypical adenomatous hyperplasia (AAH) may also be
observed. In mice, AAH is believed to precede adenoma and
adenocarcinoma formation.
The classification of proliferative pulmonary lesions of
the mouse was recently addressed by human, veterinary, and
experimental pathologists in the Mouse Models of Human
Cancers Consortium workshop.42 Consistent with the pro-
posed nomenclature, it was specifically recommended that
the term bronchioloalveolar be withheld in the mouse clas-
sification. The commonly observed benign and malignant
mouse neoplasms traditionally diagnosed as bronchioloalveo-
lar (bronchioloalveolar, alveolar/bronchiolar, A/B) adenomas
and carcinomas should be diagnosed simply as adenomas or
carcinomas with the appropriate qualification (e.g., solid,
papillary, or mixed).
Spontaneous tumors arising from the epithelium-lining
bronchi and bronchioles are exceedingly rare. Extensive hy-
perplasia of ciliated and nonciliated bronchiolar cells in
alveolar parenchyma in close vicinity of terminal bronchi-
oles—referred to as early adenomatosis—may be seen during
chemical carcinogenesis. Spontaneous lung tumors in labo-
ratory animals other than the mouse are relatively rare. In
contrast to most naturally occurring adenomas, experimen-
tally induced pulmonary adenomas in rats are not sharply
demarcated from adjacent lung tissue and may include areas
reminiscent of BAC. Experimentally induced lung tumors in
hamsters are typically more heterogeneous than in mice.43,44
INSIGHTS FROM SPONTANEOUS AND
CHEMICALLY INDUCED LUNG TUMOR
MODELS
Morphologic Heterogeneity
In response to chemical carcinogens, viruses, radiation,
mutated oncogenes, and altered tumor-suppressor genes,
mice develop adenomas that display different growth pat-
terns.45 By specifying the carcinogen, applying it at a specific
age to a particular inbred strain, and making the histologic
diagnosis at a single time after carcinogen administration, the
percentage of tumors exhibiting a solid versus papillary
growth pattern is reproducible and predictable. Factors that
determine tumor morphology can thus be elucidated.46
DIVERSE INTERACTIONS BETWEEN TUMOR
PARENCHYMAL CELLS AND STROMAL
LEUKOCYTES
Strain A mice are sensitive to lung-tumor formation,
whereas most other strains including C57BL/6 (B6) are
resistant.47,48 Chemical carcinogens produced by tobacco
combustion, including polycyclic aromatic hydrocarbons
such as 3-methylcholanthrene (MCA) and carbamates such as
urethane, provoke adenoma formation in sensitive strains.
Linkage analysis indicates that dozens of loci, called pulmo-
nary adenoma susceptibility (Pas), pulmonary adenoma re-
sistance, and susceptibility to lung cancer, govern whether
lung tumors arise after carcinogen exposure.
Inflammation encourages tumor formation in addition
to being a consequence of the damage caused by invasive
tumors. The number of peritumoral macrophages increases as
tumors progress, and macrophage depletion renders mice
resistant to tumor formation. Lymphocyte accumulations ap-
pear during tumor progression but seldom infiltrate the tumor
bed. Deletion of the Tlr4 pattern-recognition gene increases
these accumulations.49 Pas1 and other lung cancer–suscepti-
bile sites harbor genes that confer vulnerability to acute lung
injury and inflammation. The nature and strength of the
interactions between tumor parenchymal cells and infiltrating
leukocytes thus vary in different strains. Genes determining
sensitivity to neoplasia at extrapulmonary sites also reside at
the Pas, pulmonary adenoma resistance, and susceptibility to
lung cancer loci, which, along with the inflammation deter-
minants, are linearly juxtaposed and may constitute a func-
tional unit. Males and females differ in their dependence on
inflammatory mediators for tumor growth. Female mice are
more likely to get lung cancer when the antiinflammatory
Il-10 gene is deleted, whereas males are unaffected.
MOLECULAR HETEROGENEITY
Kras (codon 12 or 61) mutations are the most charac-
teristic change in gene structure in spontaneous and chemi-
cally induced mouse tumors.50,51,53,54 Variations in the nature
of the Kras mutation can directly affect tumor-growth status,
although the mechanism by which each mutation exerts
unique biological effects is unknown. For example, in mice
treated with MCA, the age (fetal or adult) at the time of
exposure determines the Kras codon 12 mutation. In lung
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tumors induced by MCA in adult BALB mice, the most
common mutation is KrasG12V, but tumors that develop after
fetal mice are transplacentally exposed to MCA have mainly
KrasG12C. Urethane induces Kras codon 61 mutations. Most
adenomas in A/J mice have a KrasQ61L substitution, but a
few have KrasQ61R. In contrast, carcinomas contain
KrasQ61R, as if the nature of the Kras mutation determined
in advance of clonal expansion whether malignant conversion
would occur. All four of these mutations, KrasG12V and -C
and KrasQ61L and -R, inhibit GTPase activity, but subtleties,
perhaps in protein stability, dictate their effects on tumor
biology. Wild-type Kras allele is a tumor-suppressor gene;
the balance between this suppressive activity versus the
enhancing activity of each particular Kras mutant may vary.
TRANSGENIC MOUSE MODELS
Lesions resembling human AAH have been observed in
several genetically engineered mouse models of lung cancer,
including those involving Kras52,55–62 fibroblast growth-fac-
tor family members (i.e., Fgf3, Fgf7, and Fgf10),63–65 myc,66
and Egf.66
The frequent development of alveolar hyperplasias in
genetically engineered mice expressing oncogenes in the lung
may be partly attributable to the frequent use of promoters
expressed in type II alveolar cells to drive oncogene expres-
sion in these mice. Whereas the SP-C promoter is expressed
primarily in type II alveolar cells, the CCSP promoter is
expressed in many transgenic lines in type II alveolar cells as
well as the tracheobronchial epithelium, which accounts for
tumors arising in these structures.64
The absence of lesions analogous to human BAC in
mice may be attributable to a fundamental difference in the
pathogenesis of lung disease in mice. A further understanding
of the pathogenesis of human BAC may allow the design of
mouse models that more accurately reflect this histological
entity.
Future Tasks
Mouse lung-tumor models are a valuable resource for
the BAC translational research community. In particular, data
can be used to translate information from clinical and epide-
miological studies in controlled and experimentally defined
environments. Future research should focus on the following
priorities: 1) increasing translational efforts between mouse
and human studies; 2) evaluating steps in tumor progression
(e.g., AAH  BAC?); 3) enhancing knowledge about pro-
genitor-cell types involved in lung tumors; 4) improving
knowledge of the molecular basis of human BAC to improve
mouse models; 5) increasing the repertoire of genetic tools to
generate future mouse models; and 6) developing novel
strategies for chemoprevention and treatment.
ORTHOTOPIC MODELS OF HUMAN LUNG
CANCER IN NUDE MICE
Models of human lung cancer growing in immune
deficient mice have also been developed, including orthotopic
models of tumor cells implanted into rodent lungs. The
rationale for organ-specific tumor implantation is that organ
microenvironment influences the phenotype of tumor cells, as
originally enunciated by Pagets’ “seed and soil” theory.67
Different techniques have been used to introduce tumors ob-
tained surgically,68 such as injection of tumor cells into rodent
airways,69–71 intrapleural implantation,72,73 and implantation
with matrigel, which is used to provide an anchor.74,75–78
The techniques needed for orthotopic models are repro-
ducible, can be performed quickly, are easily taught, and have
virtually no procedure-related animal mortality. However,
orthotopic lung cancer models are not widely used, and most
of the research and development of novel therapeutics for
lung cancer still relies on subcutaneous tumor models, which
are potentially less clinically relevant. It may be prudent to
first screen novel anticancer agents in subcutaneous tumor
models and then screen active agents in orthotopic models
before the initiation of clinical trials.
Multiple human lung cancer cell lines have been stud-
ied with orthotopic models, including NCI-H358, which was
designated by the American Type Culture Collection as a
BAC cell line.78,79 However, the pattern of growth of this cell
line injected with matrigel was from a solitary nodule to
diffuse thoracic disease. To date, there is no human BAC cell
line, which follows the classic lepidic growth pattern along
the alveolar septae, leaving interstitial structures intact.
Future Tasks
Orthotopic models also represent an important tool for
the BAC research community. Priorities at this time include
1) developing BAC cell lines for testing, because few, if any,
currently exist; 2) using orthotopic models in parallel with
other mouse lung-tumor models; and 3) exploring the use of
orthotopic models to study metastases.
REFERENCES
1. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and
Pleural Tumors, 3rd. Berlin: Springer Verlag, 1999.
2. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and patho-
logic stage but not histologic features predict outcome for bronchioloal-
veolar carcinoma. Ann Thorac Surg 2002;74:1640–1646.
3. Grossman DA, Hiti AL, McNiel EA, Ye Y, Alpaugh ML, Barsky SH.
Comparative oncological studies of feline bronchioloalveolar lung car-
cinoma, its derived cell line and xenograft. Cancer Res 2002;62:3826–
3833.
4. Hahn FF, Muggenburg BA, Griffith WC. Primary lung neoplasic in a
beagle colony. Vet Pathol 1996;33:633–638.
5. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising
incidence of bronchioloalveolar lung carcinoma and its unique clinico-
pathologic features. Cancer 1994;73:1163–1170.
6. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic
subtype and smoking history predict sensitivity to gefitinib in advanced
non-small cell lung cancer. J Clin Oncol 2004;22:1103–1109.
7. Miller VA, Patel J, Shah N, et al. The epidermal growth factor receptor
tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in
patients with bronchioalveloar cell carcinoma (BAC): preliminary re-
sults of a phase II trial (Abstract). Proc Amer Soc Clin Onc 2003:2491.
8. West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839) therapy
for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncol-
ogy Group (SWOG) Study S0126. Proc Am Soc Clin Oncol 2004;22:
7014.
9. Milton DT, Kris MG, Gomez JE, Feinstein MB. Prompt control of
bronchorrhea in patients with bronchioloalveolar carcinoma treated with
gefitinib (Iressa). Support Care Cancer 2005;13:70–72.
10. Falk RT, Pickle LW, Fonthan ET, et al. Epidemiology of bronchioal-
veolar carcinoma. Cancer Epidemiol Biomark Prevent 1992;1:339–344.
Journal of Thoracic Oncology • Vol. 1, No. 9, November Supplement 2006 Epidemiology, Pathogenesis, and Preclinical Models
Copyright © 2006 by the International Association for the Study of Lung Cancer S5
11. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer.
Cell 1996;87:159–170.
12. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung
carcinoma: K-ras mutations are constant events in the mucinous subtype.
J Pathol 1996;179:254–259.
13. Marchetti A, Pellegrini S, Bertacca G, et al. FHIT and p53 gene
abnormalities in bronchioloalveolar carcinomas. Correlations with clin-
icopathological data and K-ras mutations. J Pathol 1998;184:240–246.
14. Koga T, Hashimoto S, Sugio K, et al. Clinicopathological and molecular
evidence indicating the independence of bronchioloalveolar components
from other subtypes of human peripheral lung adenocarcinomas. Clin
Cancer Res 2001;7:1730–1738.
15. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and
non-mucinous-type adenocarcinoma of the lung: immunohistochemical
examination and K-ras gene mutation. Virchows Arch 2002;440:598–
603.
16. Dacic S, Sasatomi E, Swalsky PA, Kim DW, Finkelstein SD, Yousem
SA. Loss of heterozygosity patterns of sclerosing hemangioma of the
lung and bronchioloalveolar carcinoma indicate a similar molecular
pathogenesis. Arch Pathol Lab Med 2004;128:880–884.
17. Sasatomi E, Johnson LR, Aldeeb DN, Lomago DM, Thompson JW Jr.
Genetic profile of cumulative mutational damage associated with early
pulmonary adenocarcinoma: bronchioloalveolar carcinoma vs. stage I
invasive adenocarcinoma. Am J Surg Pathol 2004;28:1280–1288.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-
small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science 2004;304:
1497–1500.
20. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are
common in lung cancers from “never smokers” and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A
2004;101:13306–13311.
21. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small
cell lung cancer: analysis of a large series of cases and development of
a rapid and sensitive method for diagnostic screening with potential
implications on pharmacologic treatment. J Clin Oncol 2005;23:857–
865.
22. Bonne C. Morphological resemblance of pulmonary adenomatosis (jaag-
siekte) in sheep and certain cases of cancer of the lung in man. Am J
Cancer 1939;35:491.
23. Jaagsiekte sheep retrovirus and lung cancer. In Fan H (Ed.), Current
Topics in Microbiology and Immunology. Berlin: Springer-Verlag,
2003.
24. Palmarini M, Fan H. Retrovirus-induced ovine pulmonary adenocarci-
noma, an animal model for lung cancer. J Natl Cancer Inst 2001;93:
1603–1614.
25. Sharp JM, DeMartini JC. Natural history of JSRV in sheep. Curr Top
Microbiol Immunol 2003;275:55–79.
26. York DF, Vigne R, Verwoerd DW, Querat G. Nucleotide sequence of
the jaagsiekte retrovirus, an exogenous and endogenous type D and B
retrovirus of sheep and goats. J Virol 1992;66:4930–4939.
27. DeMartini JC, Bishop JV, Allen TE, et al. Jaagsiekte sheep retrovirus
proviral clone JSRV(JS7), derived from the JS7 lung tumor cell line,
induces ovine pulmonary carcinoma and is integrated into the surfactant
protein A gene. J Virol 2001;75:4239–4246.
28. Platt JA, Kraipowich N, Villafane F, DeMartini JC. Alveolar type II
cells expressing jaagsiekte sheep retrovirus capsid protein and surfactant
proteins are the predominant neoplastic cell type in ovine pulmonary
adenocarcinoma. Vet Pathol 2002;39:341–352.
29. Bai J, Bishop JV, Carlson JO, DeMartini JC. Sequence comparison of
JSRV with endogenous proviruses: envelope genotypes and a novel
ORF with similarity to a G-protein-coupled receptor. Virology 1999;
258:333–343.
30. Fan H, Palmarini M, DeMartini JC. Transformation and oncogenesis by
jaagsiekte sheep retrovirus. Curr Top Microbiol Immunol 2003;275:
139–177.
31. Rai SK, Duh FM, Vigdorovich V, Danilkovitch-Miagkova A, Lerman
MI, Miller AD. Candidate tumor suppressor HYAL2 is a glycosylphos-
phatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte
sheep retrovirus, the envelope protein of which mediates oncogenic
transformation. Proc Natl Acad Sci U S A 2001;98:4443–4448.
32. Maeda N, Palmarini M, Murgia C, Fan H. Direct transformation of
rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc Natl Acad
Sci U S A 2001;98:4449–4454.
33. Allen TE, Sherrill KJ, Crispell SM, Perrott MR, Carlson JO, DeMartini
JC. The jaagsiekte sheep retrovirus envelope gene induces transforma-
tion of the avian fibroblast cell line DF-1 but does not require a
conserved SH2 binding domain. J Gen Virol 2002;83:2733–2742.
34. Danilkovitch-Miagkova A, Duh FM, Kuzmin I, et al. Hyaluronidase 2
negatively regulates RON receptor tyrosine kinase and mediates trans-
formation of epithelial cells by jaagsiekte sheep retrovirus. Proc Natl
Acad Sci U S A 2003;100:4580–4585.
35. Palmarini M, Maeda N, Murgia C, De-Fraja C, Hofacre A, Fan H. A
phosphatidylinositol 3-kinase docking site in the cytoplasmic tail of the
Jaagsiekte sheep retrovirus transmembrane protein is essential for enve-
lope-induced transformation of NIH3T3 cells. J Virol 2001;75:11002–
11009.
36. Zavala G, Pretto C, Chow YH, et al. Relevance of Akt phosphorylation
in cell transformation induced by Jaagsiekte sheep retrovirus. Virology
2003;312:95–105.
37. Cousens C, Bishop JV, Philbey AW, et al. Analysis of integration sites
of Jaagsiekte sheep retrovirus in ovine pulmonary adenocarcinoma.
J Virol 2004;78:8506–8512.
38. Philbey AW, Cousens C, Bishop JV, DeMartini JC, Sharp JM. Multi-
clonal pattern of jaagsiekte sheep retrovirus integration sites in ovine
pulmonary adenocarcinoma. Virus Res 2006;117:254–263.
39. De las Heras M, Barsky SH, Hasleton PS, et al. Evidence for a protein
related immunologically to the jaagsiekte sheep retrovirus in some
human lung tumours. Eur Respir J 2000;16:330–332.
40. Yousem SA, Finkelstein SD, Swalsky PA, Bakker A, Ohori NP. Ab-
sence of jaagsiekte sheep retrovirus DNA and RNA in bronchioloalveo-
lar and conventional human pulmonary adenocarcinoma by PCR and
RT-PCR analysis. Hum Pathol 2001;32:1039–1042.
41. Morozov VA, Lagaye S, Lower J, Lower R. Detection and character-
ization of betaretroviral sequences, related to sheep Jaagsiekte virus, in
Africans from Nigeria and Cameroon. Virology 2004;327:162–168.
42. Nikitin AY, Alcaraz A, Anver MR, et al. Classification of proliferative
pulmonary lesions of the mouse: recommendations of the mouse models
of human cancers consortium. Cancer Res 2004;64:2307–2316.
43. Sunday ME, Willett CG, Graham SA, Oreffo VI, Linnoila RI, Witschi
H. Histochemical characterization of non-neuroendocrine tumors and
neuroendocrine cell hyperplasia induced in hamster lung by 4-(meth-
ylnitrosamino)-1-(3-pyridyl)-1-butanone with or without hyperoxia.
Am J Pathol 1995;147:740–752.
44. Rehm S. Comparative aspects of pulmonary carcinogenesis. In Jones
DL, Dungworth DL, Mohr U (Eds.), Respiratory System. Berlin: Springer-
Verlag, 1996, pp 158–173.
45. Malkinson AM. Molecular comparison of human and mouse pulmonary
adenocarcinomas. Exp Lung Res 1998;24:541–555.
46. Thaete IG, Nesbitt MN, Malkinson AM. Lung tumor structure among
inbred strains of mice: the pulmonary adenoma histologic type (Pah)
genes. Cancer Lett 1991;61:15–20.
47. Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M, Malkinson AM.
Tnfa and IL-10 deficiencies have contrasting effects on lung tumor
susceptibility: gender-dependent modulation of IL-10 haploinsuffi-
ciency. Mol Carcinog 2003;38:117–123.
48. Bauer AK, Malkinson AM, Kleeberger SR. Susceptibility to neoplastic
and non-neoplastic pulmonary diseases in mice: genetic similarities. Am
J Physiol Cell Mol Physiol 2004;287:L685–L703.
49. Bauer AK, Dixon D, DeGraff LM, et al. Toll-like receptor 4 in butylated
hydroxytoluene-induced mouse pulmonary inflammation and tumori-
genesis. J Natl Cancer Inst 2005;97:1778–1781.
50. Nuzum EO, Malkinson AM, Beer DG. Specific Ki-ras codon 61 muta-
tions may determine the development of urethan-induced mouse lung
adenomas or adenocarcinomas. Mol Carcinog 1990;3:287–295.
51. Gressani KM, Leone-Kabler S, O’Sullivan MG, Case LD, Malkinson
AM, Miller MS. Strain-dependent lung tumor formation in mice trans-
placentally exposed to 3-methylcholanthrene and post-natally exposed to
butylated hydroxytoluene. Carcinogenesis 1999;20:2159–2165.
52. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic
regression of lung adenocarcinomas by regulation of a K-Ras transgene
Christiani et al. Journal of Thoracic Oncology • Vol. 1, No. 9, November Supplement 2006
Copyright © 2006 by the International Association for the Study of Lung CancerS6
in the presence and absence of tumor suppressor genes. Genes Dev
2001;15:3249–3262.
53. Zhang Z, Wang Y, Vikis H, et al. Wildtype Kras2 can inhibit lung
carcinogenesis in mice. Nature Gen 2001;29:25–33.
54. Floyd HS, Farnsworth CL, Kock ND, et al. Conditional expression of the
mutant Ki-ras(G12C) allele results in formation of benign lung adeno-
mas: development of a novel mouse lung tumor model. Carcinogenesis
2005;26:2196–2206.
55. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an
endogenous K-ras oncogene is highly dependent on cellular context.
Cancer Cell 2003;4:111–120.
56. Jackson E, Willis N, Mercer K, et al. Analysis of lung tumor initiation
and progression using conditional expression of oncogenic K-ras. Genes
Dev 2001;15:3243–3248.
57. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the
K-ras oncogene causes early onset lung cancer in mice. Nature 2001;
410:1111–1116.
58. Meuwissen R, Linn S, van der Valk M, Mooi W, Berns A. Mouse model
for lung tumorigenesis through Cre/Lox controlled sporadic activation of
the K-Ras oncogene. Oncogene 2001;20:6551–6558.
59. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic
K-ras(G12D) stimulates prolifertion and widespread neoplastic and
developmental defects. Cancer Cell 2004;5:375–387.
60. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH. The
pattern of K-ras mutation in pulmonary adenocarcinoma defines a new
pathway of tumour development in the human lung. J Pathol 1997;181:
401–404.
61. Sagawa M, Saito Y, Fujimura S, Linnoila RI. K-ras point mutation
occurs in the early stage of carcinogenesis in lung cancer. Br J Cancer
1998;77:720–723.
62. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in
atypical alveolar hyperplasias of the human lung. Cancer Res 1996;56:
2224–2228.
63. Clark J, Tichelaar J, Wert S, et al. FGF-10 disrupts lung morphogenesis
and causes pulmonary adenomas in vivo. Am J Physiol Cell Mol Physiol
2001;280:L705–L715.
64. Tichelaar J, Lu W, Whitsett J. Conditional expression of fibroblast
growth factor-7 in the developing and mature lung. J Biol Chem
2000;275:11858–11864.
65. Zhao B, Chua S, Burcin M, et al. Phenotypic consequences of lung-
specific inducible expression of FGF-3. Proc Natl Acad Sci U S A
2001;98:5898–5903.
66. Ehrhardt A, Bartels T, Geick A, Klocke R, Paul D, Halter R. Develop-
ment of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic
mice overexpressing murine c-myc and epidermal growth factor in
alveolar type II pneumocytes. Br J Cancer 2001;84:813–818.
67. Paget S. The distribution of secondary growths in cancer of the breast.
Cancer Metastasis Rev 1989;8:98–101.
68. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug
discovery and evaluation: a bridge to the clinic. Invest New Drugs
1999;17:343–359.
69. McLemore TL, Liu MC, Blacker PC, et al. Novel intrapulmonary model
for orthotopic propagation of human lung cancers in athymic nude mice.
Cancer Res 1987;47:5132–5140.
70. Howard RB, Chu H, Zeligman BE, et al. Irradiated nude rat model for
orthotopic human lung cancers. Cancer Res 1991;51:3274–3280.
71. Hastings RH, Burton DW, Quintana RA, Biederman E, Gujral A, Deftos
LJ. Parathyroid hormone-related protein regulates the growth of ortho-
topic human lung tumors in athymic mice. Cancer 2001;92:1402–1410.
72. McLemore TL, Eggleston JC, Shoemaker RH, et al. Comparison of
intrapulmonary, percutaneous, intrathoracic, and subcutaneous models
for the propagation of human pulmonary and nonpulmonary cancer cell
lines in athymic nude mice. Cancer Res 1988;48:2880–2886.
73. Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierre A, Atassi G.
Histology and sensitivity to anticancer drugs of two human non-small
cell lung carcinomas implanted in the pleural cavity of nude mice. Clin
Cancer Res 2000;6:297–304.
74. Doki Y, Muramaki K, Yamaura T, Sugiyama K, Misaki T, Saiki I.
Mediastinal lymph node metastatis model by orthotopic intrapulmonary
implantation of Lewis lung carcinoma cells in mice. Br J Cancer
1999;79:1121–1126.
75. Wang HY, Ross HM, Ng B, Burt ME. Establishment of an experimental
intrapulmonary tumor nodule model. Ann Thorac Surg 1997;64:216–
219.
76. Miyoshi T, Kondo K, Ishikura H, Kinoshita H, Matsumori Y, Monden
Y. SCID mouse lymphogenous metastatic model of human lung cancer
constructed using orthotopic inoculation of cancer cells. Anticancer Res
2000;20:161–163.
77. Boehle AS, Dohrmann P, Leuschner I, Kalthoff H, Henne-Bruns D. An
improved orthotpoic xenotransplant procedure for human lung cancer in
SCID bg mice. Ann Thorac Surg 2000;69:1010–1015.
78. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to
study the biology and therapy of primary human lung cancer in nude
mice. Clin Cancer Res 2003;9:5532–5539.
79. Onn A, Isobe T, Roach JS, et al. Blockade of EGFR tyrosine kinase does
not predict outcome in an orthotopic model of human lung cancer
(Abstract). Proc AACR 2003;44:1076.
Journal of Thoracic Oncology • Vol. 1, No. 9, November Supplement 2006 Epidemiology, Pathogenesis, and Preclinical Models
Copyright © 2006 by the International Association for the Study of Lung Cancer S7
